Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.

Roche has struck a deal to unload a plant in Spain to Recipharm, a move that will save 200 jobs as it sheds unneeded small-molecule facilities.

In a biosimilars case with blockbuster implications, Pfizer sued J&J, calling its strategy for fighting off Remicade biosimilars "anticompetitive.…

England's cost watchdog NICE has approved Bristol-Myers Squibb's Opdivo as a second-line treatment, but with strict conditions.

After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing…

After years of being recruited, pro athlete Deion Sanders is doing some recruiting of his own—for Botox.

A Nevada judge denied the drug industry's request for an injunction that would have stopped a new pricing-disclosure law in its tracks.

Kåre Schultz has yet to take over at beleaguered Teva, but he is already getting advice on what to do from some of this investors.